Bouchard, C., Miyazaki, K., Tang, C., Martins, K., Wang, X., Medley-Wilson, S., Briggs, P. (2026). HIGHLIGHT 1: A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor–positive breast cancer who are receiving adjuvant endocrine therapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps642